Home > 2020 > April 2020
April 2020
April 2020 was another great month for drug discovery publications, with several interesting first disclosures of clinical candidates and a variety of uncommon chemical motifs that will pique most chemists’ interest. Here’s a visual summary of the molecules, with some comments and links to the articles below:
Join the Drug Hunter mailing list, trusted by >4,000 drug hunters worldwide. Drug Hunter content only, unsubscribe anytime.
nominate a molecule
Encountered an interesting new molecule? Let your community know!
become a reviewer
Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.
past molecules of the month
Check out previous selections below.
molecules of the year nominees
Previous selections for Drug Hunter’s Molecule of the Year below.
hall of fame
molecules of the year
Previous selections for Drug Hunter’s Molecule of the Year below.
Work smarter in two minutes. Join >4,000 drug hunters from every major biopharma company in the world getting drug discovery updates through our Drug Hunter e-mail newsletter. Unsubscribe anytime.
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others
